Hilltop National Bank Makes New Investment in Vertex Pharmaceuticals Incorporated $VRTX

Hilltop National Bank bought a new position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 272 shares of the pharmaceutical company’s stock, valued at approximately $121,000.

A number of other large investors have also added to or reduced their stakes in VRTX. Brighton Jones LLC grew its holdings in shares of Vertex Pharmaceuticals by 15.0% during the 4th quarter. Brighton Jones LLC now owns 4,427 shares of the pharmaceutical company’s stock worth $1,783,000 after purchasing an additional 579 shares in the last quarter. NBC Securities Inc. acquired a new stake in Vertex Pharmaceuticals during the first quarter worth about $167,000. RFG Advisory LLC increased its holdings in Vertex Pharmaceuticals by 12.1% in the 1st quarter. RFG Advisory LLC now owns 757 shares of the pharmaceutical company’s stock valued at $367,000 after buying an additional 82 shares during the period. Chesley Taft & Associates LLC acquired a new position in shares of Vertex Pharmaceuticals in the 1st quarter valued at approximately $236,000. Finally, Foster Group Inc. bought a new stake in shares of Vertex Pharmaceuticals during the 1st quarter worth approximately $255,000. Institutional investors and hedge funds own 90.96% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on VRTX. Truist Financial set a $490.00 price objective on shares of Vertex Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, August 5th. Stifel Nicolaus reduced their target price on Vertex Pharmaceuticals from $494.00 to $455.00 and set a “hold” rating on the stock in a report on Tuesday, August 5th. Weiss Ratings reissued a “hold (c+)” rating on shares of Vertex Pharmaceuticals in a report on Saturday, September 27th. Canaccord Genuity Group dropped their price objective on Vertex Pharmaceuticals from $424.00 to $411.00 and set a “hold” rating for the company in a research report on Wednesday, August 6th. Finally, Evercore ISI decreased their target price on Vertex Pharmaceuticals from $510.00 to $475.00 and set an “outperform” rating on the stock in a research report on Thursday, September 11th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and twelve have given a Hold rating to the stock. Based on data from MarketBeat, Vertex Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $493.81.

Vertex Pharmaceuticals Stock Performance

Shares of VRTX opened at $403.30 on Friday. The firm has a market cap of $103.40 billion, a PE ratio of 28.83 and a beta of 0.43. Vertex Pharmaceuticals Incorporated has a 52-week low of $362.50 and a 52-week high of $519.88. The business’s 50 day moving average price is $399.12 and its two-hundred day moving average price is $442.50.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its earnings results on Monday, August 4th. The pharmaceutical company reported $4.52 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.24 by $0.28. The company had revenue of $2.94 billion for the quarter, compared to the consensus estimate of $2.90 billion. Vertex Pharmaceuticals had a net margin of 31.86% and a return on equity of 23.91%. Vertex Pharmaceuticals’s quarterly revenue was up 11.3% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($12.83) EPS. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. Research analysts predict that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current fiscal year.

Insider Activity

In other Vertex Pharmaceuticals news, Director Bruce I. Sachs purchased 5,000 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Wednesday, August 6th. The stock was acquired at an average price of $389.68 per share, with a total value of $1,948,400.00. Following the transaction, the director owned 45,000 shares in the company, valued at $17,535,600. This trade represents a 12.50% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.20% of the stock is currently owned by corporate insiders.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.